Skip to content
2000
Volume 19, Issue 5
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Background: The mitochondria may very well determine the final commitment of the cell to death, particularly in times of energy stress. Cancer chemotherapeutics such as the anthracycline doxorubicin perturb mitochondrial structure and function in tumour cells, as evidenced in osteosarcoma, for which doxorubicin is used clinically as frontline therapy. This same mechanism of cell inhibition is also pertinent to doxorubicin's primary cause of side-effects, that to the cardiac tissue, culminating in such dire events as congestive heart failure. Reactive oxygen species are partly to blame for this effect on the mitochondria, which impact the electron transport chain. Objective: As this review highlights that, there is much more to be learnt about the mitochondria and how it is affected by such effective but toxic drugs as doxorubicin. Conclusion: Such information will aid researchers who search for cancer treatment able to preserve mitochondrial number and function in normal cells.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450116666150416115852
2018-04-01
2025-10-27
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450116666150416115852
Loading

  • Article Type:
    Review Article
Keyword(s): apoptosis; bone; cancer; Doxorubicin; mitochondria; osteosarcoma
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test